Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Scientists map steps to block key enzyme action in heart failure

Scientists map steps to block key enzyme action in heart failure

November 12, 2008

S-nitrosylation of cysteine 181mimics action of Viagra-like drugs, which have been shown to rescue failing hearts

Taking a cue from the way drugs like Viagra put the biological brakes on a key enzyme involved in heart failure, scientists at Johns Hopkins have mapped out a key chemical step involved in blocking the enzyme.




The Johns Hopkins team reports how the enzyme, phosphodiesterase 5, or PDE5A, slows down the breakdown of another, more vital compound in the body, cyclic guanosine monophosphate (cyclic GMP) which influences a variety of biological activities, including cell growth and muscle contraction. A buildup of cyclic GMP limits stress and overgrowth of heart tissue.

PDE5A is the same enzyme that earlier Johns Hopkins work in mice showed is slowed down by the drug sildenafil (Viagra), leading to a reverse of tissue damage from heart enlargement, or hypertrophy, and potentially heart failure. What the scientists are seeing more broadly in this new work is most likely the same braking mechanism, but through a natural chemical reaction in the cell instead of through a synthetic chemical.

In the latest study, to be presented Nov. 11 at the American Heart Association's annual Scientific Sessions in New Orleans, the Johns Hopkins team of protein biochemists confirmed precisely where a sulfur- and nitrogen-containing molecule, or S-nitrosyl group, chemically alters the enzyme's amino-acid building blocks. And they showed that so-called S-nitrosylation of amino acid cysteine 181 results in a 25 percent decrease in PDE5A activity, pinpointing how the enzyme's action is suppressed.

"Knowing the molecular make-up and activity of a protein is critical to understanding heart failure because these problem-specific biochemical reactions are magnified in the disease," says senior study investigator Jennifer Van Eyk, Ph.D., a professor at the Johns Hopkins University School of Medicine and its Heart and Vascular Institute.

"Targeted drug therapies can now be developed and tested to work specifically on cysteine 181, to block the PDE5A enzyme, lower the breakdown of cyclic GMP, and potentially stall progression of heart failure and hypertrophy," adds Van Eyk, director of the Johns Hopkins NHLBI Proteomics Group and the Proteomics Center at Johns Hopkins Bayview Medical Center.

Van Eyk says that previous research by co-investigator Hunter Champion, M.D., Ph.D., had shown that other chemical pathways in cyclic GMP were controlled by the placement of the sulfur-nitrosyl combo, prompting her team to investigate if PDE5A was similarly influenced.

In the first of a series of experiments led by biochemist Christopher Murray, M.Sc., a doctoral candidate at Johns Hopkins, test-tube samples of the enzyme and cyclic GMP were exposed to nitric oxide, which stimulates S-nitrosylation, alone and in the presence of sildenafil. Results showed that PDE5A activity, as measured by the breakdown of cyclic GMP, was at a maximum 100 percent if left untreated with no nitric oxide, but enzyme activity dropped by 25 percent once it was added.

"This was the first solid evidence of S-nitrosylation in PDE5A," says Murray, who, after having confirmed what was happening to the enyzme, proceeded to map out just where on the enzyme S-nitrosylation was taking place.

As cysteine is the only amino acid to which an S-nitrosyl group can attach, Murray's next step was to narrow the search from among the 20-plus possible cysteine locations found in PDE5A.

Two potential candidates emerged for having undergone S-nitrosylation, a cysteine located at the 181st position in the amino acid chain, and another cysteine at site 210. After exposing all PDE5A cysteines to possible S-nitrosylation and then substituting any attached nitrosyl groups with a chemical tag to extract any chemically modified parts, researchers used a mass spectrometry device to tell one amino acid from another.

In a separate experiment, Murray then determined which one of the two cysteines, or both, was being altered. Enzyme pools specific to each cysteine were created. One pool had cysteine 181 blocked, leaving only cysteine 210 available for possible chemical modification, while the other pool had cysteine 210 blocked, leaving open cysteine 181.

Separate chemical attempts at S-nitrosylation of each pool gradually showed that if cysteine 181 was unavailable to react, then enzymatic activity proceeded at the same rate as in a control group with all cysteines free to react.

Researchers say their next steps are to investigate how PDE5A affects where cyclic GMP is broken down or made, with the goal of determining if the enzyme also controls the known cell pooling of the compound. Future studies will also examine other potential effects of PDE5A production, and how alterations to its structure affect its function.

Study co-investigator and cardiologist David Kass, M.D., in whose lab in 2005 much of the original work on sildenafil and PDE5A was performed, also plans to develop a mouse model with blocked cysteine 181 to see what happens when these mice develop heart failure.

Johns Hopkins Medical Institutions



Related Heart Failure Current Events and Heart Failure News Articles Heart Failure Current Events and Heart Failure News RSS Heart Failure Current Events and Heart Failure News RSS
Mount Sinai researchers are the first to identify heart abnormalities in World Trade Center workers
Researchers from Mount Sinai School of Medicine are presenting more than 20 ground-breaking studies at the American College of Cardiology (ACC) 59th annual scientific session (ACC.10) in Atlanta.

As Girth Grows, Risk of Sudden Cardiac Death Shrinks
Obesity has long been identified as a risk factor for cardiovascular disease and heart failure. But, a new study conducted by researchers at the University of Rochester Medical Center found that being skinny confers no advantage when it comes to the risk of dying suddenly from cardiac causes.

Researchers discover chemical that may protect hearts of muscular dystrophy patients
Researchers at the University of Minnesota Medical School have discovered a chemical that may, over the long term, protect the hearts of Duchenne muscular dystrophy patients - a fatal and most common form of muscular dystrophy in children.

Research points to way to improve heart treatment
Current drugs used to treat heart failure and arrhythmias (irregular heartbeat) have limited effectiveness and have side effects.

A full house raises risk of hospital deaths
Admission to a hospital when most of the beds are already full can be deadly for patients, according to a new University of Michigan Health System study showing high occupancy increases the risk of dying in the hospital by 5.6 percent.

Transcendental Meditation activates default mode network, the brain's natural ground state
A new EEG study conducted on college students at American University found they could more highly activate the default mode network, a suggested natural "ground state" of the brain, during their practice of the Transcendental Meditation technique.

Beta blocker therapy underused in heart failure patients
New Saint Louis University research has found that beta blockers, a class of drugs used to prevent the progression of heart failure and manage arrhythmias (irregular heart beat) and hypertension (high blood pressure), are underused in heart failure patients who receive implantable cardiac devices.

Safety data favor norepinephrine over dopamine for shock
Physicians treating patients with shock should consider norepinephrine instead of dopamine as a tool for stabilizing blood pressure, according to an editorial in the March 4, 2010, issue of the New England Journal of Medicine (NEJM).

Cluster of 'critical' follow-up evaluations may improve outlook for hospitalized HF patients
Heart failure is by far the most prevalent chronic cardiac condition. Around 30 million people in Europe have heart failure and its incidence is still increasing: more cases are being identified, more people are living to an old age, and more are surviving a heart attack but with damage to the heart muscle.

Bone marrow cell transplants to benefit those with heart disease
Two studies published in the latest issue of Cell Transplantation (18:12) may lead to new treatments for the treatment of heart diseases.
More Heart Failure Current Events and Heart Failure News Articles
Success with Heart Failure (mass mkt ed): Help and Hope for Those with Congestive Heart Failure

Success with Heart Failure (mass mkt ed): Help and Hope for Those with Congestive Heart Failure
by Marc Silver (Author)

Up-to-date information on available and forthcoming medical and surgical treatments.

How attitude and emotion affect heart failure--and what you can do to stay positive.

Tips for adopting a heart-healthy diet and lifestyle.

Ways to forge a positive working relationship with your doctor or cardiologist.



Heart Failure: Pathophysiology, Molecular Biology, and Clinical Management (HEART FAILURE: PATHOPHYSIOLOGY, MOLEC BIOL & CLIN MGT)

Heart Failure: Pathophysiology, Molecular Biology, and Clinical Management (HEART FAILURE: PATHOPHYSIOLOGY, MOLEC BIOL & CLIN MGT)
by Arnold M Katz (Author), Marvin A Konstam (Author)

This Second Edition of Dr. Katz's highly acclaimed text has been thoroughly revised to incorporate the latest advances in the study and treatment of heart failure. The book explains the pathophysiology, molecular mechanisms, clinical manifestations, and therapy of heart failure in an integrated, reader-friendly manner that is accessible to both clinicians and basic scientists. More than 100 illustrations, most created for this book by the authors, complement the text. This edition has been completely reorganized. Chapters describe the hemodynamic basis for the clinical manifestations of heart failure; the neurohumoral responses in heart failure and key signaling pathways that mediate functional responses; the proliferative responses in failing hearts; the cellular and molecular...

The Cleveland Clinic Guide to Heart Failure (Cleveland Clinic Guides)

The Cleveland Clinic Guide to Heart Failure (Cleveland Clinic Guides)
by Randall Starling (Author)

Expert medical advice from the #1 heart center in America for 14 years in a row

For the 5 million people with heart failure, there’s new reason for hope: recent medical advances have revolutionized how this condition is managed.

In The Cleveland Clinic Guide to Heart Failure, Dr. Randall Starling, one of the foremost authorities on heart health, provides authoritative advice to help people survive heart failure and enjoy a good quality of life. This comprehensive resource gives readers the cutting-edge medical guidance Dr. Starling offers his patients, including:

Insight into what causes heart failureThe latest breakthrough studies – and what those discoveries mean for the future of this diseaseReliable guidance on diagnostic tests and treatment optionsPersonal stories of...

  Heart Failure: A Critical Inquiry into American Medicine and the Revolution in Heart Care
by Thomas J. Moore (Author)



100 Questions & Answers About Congestive Heart Failure

100 Questions & Answers About Congestive Heart Failure
by Campion Quinn (Author)

Whether you or a loved one has been diagnosed with congestive heart failure, the number and type of diagnosis and treatment options can be overwhelming. This invaluable resource offers the guidance and advice you need. Written by a prominent physician and by a leader in patient support for this devastating disease, 100 Questions & Answers About Congestive Heart Failure gives you authoritative, practical answers to your questions, including causes, diagnosis, treatment options, quality of life, care giving, sources of support, and much more.

Cardiac Disorders: Heart Failure (116) CD-ROM

Cardiac Disorders: Heart Failure (116) CD-ROM
by Concept Media, a division of Jobson Medical Information LLC

4 CD series including these programs: [116.1] Heart Failure: Part One; [116.2] Heart Failure: Part Two; ; and instructor's guides in PDF format and self-grading description

Heart Failure: A Practical Approach to Treatment

Heart Failure: A Practical Approach to Treatment
by William Abraham (Author), Henry Krum (Author)

The definitive one-stop guide to treating -- and preventing -- heart failure

This practical reference provides all the expert guidance and up-to-the-minute clinical perspectives you need to diagnose, treat, and manage patients with heart failure. A major focus of the book is integration of various management approaches to maximize patient benefit. Coverage begins with a brief introduction to the incidence and causes of heart failure, then quickly moves into a more thorough clinical overview of symptom evaluation, pharmacologic and non-pharmacologic treatment methods, hospitalization, surgical treatments, and more.

Features:

Clear, step-by-step coverage of prevention and all treatment modalities with evidence-based recommendations Full...

Congestive Heart Failure Awareness Ribbon Mouse Pad

Congestive Heart Failure Awareness Ribbon Mouse Pad
by MyHeritageWear.com

The Congestive Heart Failure Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Congestive Heart Failure Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Congestive Heart Failure Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness!

Congestive Heart Failure (Have A Heart Series)

Congestive Heart Failure (Have A Heart Series)
Also With: Mark Baer (Producer), Dr. Gerry Maddoux (Writer)

Believe it or not, congestive heart failure is the most common admitting diagnosis to the hospital in the 65-and-older population. It is due to one or several abnormalities of the heart or blood vessels, causing water to be pushed into the tissues, including the air pockets of the lungs. Most of these conditions can be prevented. Almost all can be effectively treated.

If so, why is it the most prevalent admission diagnosis to the hospital as we age? Because doctors h ave precious little time to properly educate you, the patient, about what to avoid, what to look for, and how to live comfortably with this problem.

This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply.

Heart Failure [Explicit]

Heart Failure [Explicit]
Mani Dots (Primary Contributor)



© 2010 BrightSurf.com